Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
- Sponsor
- Bayer
- Study ID
- NCT01447043
- Status
- Completed
Conditions
- Ophthalmology, Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab — DRUGPatients with wet AMD treated with ranibizumab as prescribed by physician
Study Details
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.
Key Dates
- First listed
- Oct 5, 2011
- Start date
- Jan 31, 2009
- Status verified
- Jan 2014
- Primary completion
- Aug 31, 2011
- Completion
- Nov 30, 2012
Study Design
- Enrollment
- 2,609 participants (actual)
Arms
- Arm: Group 1
Primary Outcome Measure
Changes in visual acuity after start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard [ Time Frame: Baseline and 24 months ]